Companies › AvenCell Europe
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Allo-RevCAR01-T-CD123 Allogeneic multi-edited CAR-T cells with reversed CAR (RevCAR) bridged to CD123 via R-TM12 | CD123 | Phase 1 | Acute Myeloid Leukemia, in Relapse | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05949125 | Allo-RevCAR01-T-CD123 | Phase 1 | Acute Myeloid Leukemia, in Relapse | Oncology | May 2027 |
Chongqing Precision Biotech Cellectis Gilead Sciences MacroGenics
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.